Article Text

Download PDFPDF
4CPS-217 Hepatitis b treatment: towards effectiveness and adherence
  1. B Lopez Centeno,
  2. V Alonso Castro,
  3. A Gil Martín,
  4. I Martín Casasempere,
  5. A Aranguren Oyarzábal,
  6. MJCalvo Alcántara
  1. Subdirección General de Farmacia y Productos Sanitarios. SERMAS, Farmacia Hospitalaria, Madrid, Spain


Background Although hepatitis B (HB) drugs have strong antiviral activity, they cannot eradicate the virus, so they must be administered for long periods of time, making long-term adherence difficult to maintain. Non-adherent patients are more likely to have virologic failure, so it is necessary to promote an optimal adherence to treatments.

Purpose To describe the evolution of HB treatment management from a regional perspective, and to step beyond health outcomes (effectiveness and adherence) using integrated patient-centred computer tools.

Material and methods Descriptive study of the information obtained by the indicators that hospital pharmacies submit to the Regional Pharmacy Department every 3 months. These are indicators of the most relevant pathologies, including HB. Variables collected: since 2010 the total cost of antiviral treatment, number of average dispensed patients and cost per average dispensed patient/year; and since 2015, the percentage of patients with treatment and virological response (viral DNA <20 IU/ml) and the percentage of patients with treatment and adherence ≥90% (records of dispensing).

Results From 2010 to 2016, HB treatment expenditure has decreased by 35%. Patients with HB treatment have increased by 89% (1,594 patients in 2010 and 3019 in 2016). The cost per average dispensed patient has been 18% lower in 2016 than in 2010 (€3728 in 2010 and €3064 in 2016).

In 2015, the percentage of patients with virological response was 89.9% (range: 71%–98.7%) and this increased to 91.6% (range: 72%–100%) in 2016, which means an improvement of 1.8 percentage points. The percentage of patients with adherence ≥90% was 93.5% (range: 84.6%–100%) and decreased to 93.2% (range: 82.8%–100%) to next year, decreasing by 0.3 percentage points.

Conclusion The cost per patient has been reduced without decreasing the effectiveness, at least in the last years, with 91% of patients with virological response and 93% adherence.

Making progress in getting results in effectiveness and adherence adds value to merely economic indicators and allows clinical professionals useful tools for the management of therapeutic resources.

References and/or Acknowledgements Hospital Pharmacy Indicators Working Group.

No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.